These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Ongoing, reported early 2004-000299-15 A double-blind, dose-response, phase II, multicentre study of radium-223 (Alpharadin TM ) for the palliation of painful bone metastases in hormone refractory prostate cancer patients not-yet-due
Listed as ongoing, but also has a completion date and reported results 2005-003680-22 A double blind, randomised, dose finding, repeat dose, phase II, multicentre study of Alpharadin TM for the treatment of patients with hormone refractory prostate cancer and skeletal metastases. 2009-12-04 bad-data
Listed as ongoing, but also has a completion date and reported results 2007-006195-11 A double-blind, randomised, multiple dose, Phase III, multicentre study of Alpharadin in the treatment of patients with symptomatic hormone refractory prostate cancer with skeletal metastases. 2014-02-13 bad-data
Reported results 2009-012189-30 An open-label Phase IIa, non-randomised, study of Alpharadin in breast cancer patients with bone dominant disease who are no longer considered suitable for endocrine therapy 2012-02-16 due-trials